【レポートの概要(一部)】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: mAbs: Overview
• Evolution of mAb therapeutics
• Types of mAbs
• Conjugated cancer therapies using mAbs
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs
PART 08: Market segmentation by application
• Global oncology mAbs market
• Global autoimmune and inflammatory mAbs market
• TNF inhibitors
• IL-1 blockers
• PDE4 inhibitors
• Global respiratory mAbs market
• Global ophthalmology mAbs market
PART 09: Geographical segmentation
• Global mAbs market by geographical segmentation 2015-2020
• mAbs market in Americas
• mAbs market in US
• mAbs market in EMEA
• mAbs market in APAC
PART 10: Key leading countries
PART 11: Pipeline portfolio
PART 12: Market drivers
• Reimbursement benefits for mAbs and its biosimilars
• Special regulatory drug designations
• Increase in demand for ADCs
• Increase in industry-academia collaborations
PART 13: Impact of drivers
PART 14: Market challenges0
• Absence of adequate diagnosis and screening procedures
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Emergence of biosimilars
• Growing focus of vendors on untapped markets
• Focus on novel mechanisms
• Joint ventures and partnerships for R&D
• Emergence of targeted and combination therapies
PART 17: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Amgen
• Merck
• BMS
• Other prominent vendors
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for mAbs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Patent expiries of top selling mAbs by 2020 in US
Exhibit 09: Patent expiries of top selling mAbs by 2020 in Europe
Exhibit 10: Global mAbs market snapshot: Developed and emerging markets 2015
Exhibit 11: Global mAbs market 2015-2020 ($ billions)
Exhibit 12: Few patient assistance programs offered by various companies
Exhibit 13: Few awareness programs for various cancers, respiratory, and ophthalmology diseases
Exhibit 14: Impact of drivers and challenges on global mAbs market
Exhibit 15: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 16: Opportunities in mAbs industry today
Exhibit 17: Five forces analysis
Exhibit 18: Approved naked mAbs by US FDA and EU
Exhibit 19: Global mAbs market: Segmentation by application (2015-2020)
Exhibit 20: Global mAbs market: Segmentation by application 2015
Exhibit 21: Global mAbs market segmentation: Growth cycle analysis
Exhibit 22: Annual treatment cost per patient for various oncology drugs 2014
Exhibit 23: Global oncology mAbs market 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis of global oncology mAbs market by type of application
Exhibit 25: Market segmentation by MOA
Exhibit 26: Population aged 60 years and over (millions)
Exhibit 27: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 28: Global autoimmune and inflammatory mAbs market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global autoimmune and inflammatory mAbs market by application
Exhibit 30: Global autoimmune and inflammatory mAbs market segmentation by MOA
Exhibit 31: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 32: Global autoimmune and inflammatory mAbs market share by MOA 2015
Exhibit 33: Global respiratory mAbs market 2015-2020 ($ billions)
Exhibit 34: Opportunity analysis of global respiratory mAbs market by application
Exhibit 35: Global mAbs market segmentation by application 2015
Exhibit 36: Global ophthalmology mAbs market 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of global ophthalmology mAbs market by application
Exhibit 38: Global mAbs market: Geography outlook (2015-2020)
Exhibit 39: Global mAbs market: Geography outlook 2015
Exhibit 40: Revenue/growth outlook in different countries/regions 2015
Exhibit 41: mAbs market in Americas 2015-2020 ($ billions)
Exhibit 42: mAbs market in Americas by country 2015
Exhibit 43: mAbs market in US 2015-2020 ($ billions)
Exhibit 44: mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 45: mAbs market in EMEA by country 2015
Exhibit 46: Number of individuals treated with Herceptin through patient assistance programs in China
Exhibit 47: mAbs market in APAC 2015-2020 ($ billions)
Exhibit 48: mAbs market in APAC by country 2015
Exhibit 49: Global mAbs market by geographical segmentation 2015
Exhibit 50: Global mAbs market by geographical segmentation 2020
Exhibit 51: Global mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 52: Key leading countries
Exhibit 53: Pipeline share of global mAbs market 2015
Exhibit 54: Phase III pipeline molecules for mAbs
Exhibit 55: Phase II pipeline molecules for mAbs
Exhibit 56: Phase I pipeline molecules for mAbs
Exhibit 57: Special regulatory designations approved by US FDA
Exhibit 58: Special regulatory designations approved by EU
Exhibit 59: Impact of drivers
Exhibit 60: Impact of drivers and challenges
Exhibit 61: Expected combination regimen launches in oncology
Exhibit 62: Global mAbs market: Impact assessment of top trends 2015
Exhibit 63: Market presence of vendors in various therapy areas 2015
Exhibit 64: Market share analysis 2015
Exhibit 65: YoY sales comparison of top ten mAbs 2013-2015 ($ billions)
Exhibit 66: Competitive assessment of vendors
Exhibit 67: Key vendors: Geographical presence 2015
Exhibit 68: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 69: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 70: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 72: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 73: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Lucentis 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Xolair 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 79: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla 2015
Exhibit 80: Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 81: Actemra/RoActemra geographic segmentation by revenue 2015
Exhibit 82: F Hoffmann-La Roche: Metrics analysis
Exhibit 83: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 84: AbbVie: YoY revenue and growth rate of Humira (US) 2013-2015 ($ billions)
Exhibit 85: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
Exhibit 86: AbbVie: YoY revenue and growth rate of Synagis 2013-2015 ($ millions)
Exhibit 87: AbbVie: Metrics analysis
Exhibit 88: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
Exhibit 89: Johnson & Johnson: YoY growth rate and revenue of Remicade (US) 2013-2015 ($ billions)
Exhibit 90: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
Exhibit 91: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 92: Johnson & Johnson: YoY growth rate and revenue of Stelara (US) 2013-2015 ($ millions)
Exhibit 93: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
Exhibit 94: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ millions)
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (US) 2013-2015 ($ millions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2013-2015 ($ millions)
Exhibit 97: Johnson & Johnson: Metrics analysis
Exhibit 98: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 99: Amgen: Geographic segmentation of Xgeva 2015
Exhibit 100: Amgen: YoY growth and revenue generated from net product sales of Prolia 2013-2015 ($ billions)
Exhibit 101: Amgen: Geographical segmentation of Prolia 2015
Exhibit 102: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2013-2015 ($ millions)
Exhibit 103: Amgen: Geographical segmentation of Vectibix 2015
Exhibit 104: Amgen: Metrics analysis
Exhibit 105: Merck: YoY revenue and growth rate of Remicade (Europe, Russia, and Turkey) 2013-2015 ($ billions)
Exhibit 106: Merck: YoY revenue and growth rate of Simponi (Europe, Russia, and Turkey) 2013-2015 ($ millions)
Exhibit 107: Merck: Metrics analysis
Exhibit 108: BMS: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ billions)
Exhibit 109: BMS: Geographical segmentation of Yervoy 2015
Exhibit 110: BMS: YoY Revenue and growth rate of Erbitux in US and Canada 2013-2015 ($ millions)
Exhibit 111: BMS: Geographical segmentation of Yervoy 2015
Exhibit 112: BMS: Geographical segmentation of Opdivo 2015
Exhibit 113: BMS: Metrics analysis
【レポート販売概要】
■ タイトル:モノクローナル抗体(mAbs)の世界市場2016-2020■ 英文:Global Monoclonal Antibodies Market 2016-2020
■ 発行日:2016年7月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9857
■ 調査対象地域:グローバル
- 世界の医療抗菌性コーティング市場動向(2012-2016)TechNavio's analysts forecast the Global Medical Antimicrobial Coatings market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of hospital-acquired infection. The Global Medical Antimicrobial Coatings market has also been witnessing increasing partnership activities among vendors. However, the stri …
- 幹細胞治療の世界市場展望Stem cells are specialized cells that can differentiate into other cells without losing their identity. They have been found to be present in animals as well as humans and most of the work has been done on mice. Investigators have found that stem cells are part of repair system and helps in maintaining the normal bodily functions. They divide to give rise to two cells out of which one remains the …
- ネットワークコンサルティングの世界市場2017-2021About Network ConsultingNetwork consulting services refer to the advisory services provided to help companies analyze and improve the operational performance and technology strategies. The services in this segment are focused on areas such as e-commerce, telecommunications, hardware system design and implementation, software design, acquisition and implementation, website design, and operation. Te …
- 主要先進国における膵臓癌(膵癌)治療動向(~2019)Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant Summary GBI Research, the leading business intelligence provider, has released its latest research,‘Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets …
- コントロールバルブの世界市場2016-2020:スライディングシャフトコントロールバルブ、回転シャフトコントロールバルブAbout Control Valves Control valves are devices that automatically regulate the flow rate, temperature, and pressure of liquids or gases based on an algorithm that adjusts the desired variable. Sensors detect changes in the flow of a substance and send out signals that control the operation of valves. Technavio’s analysts forecast the global control valves market to grow at a CAGR of 5.56% during …
- 車両整備用製品の世界市場予測(~2027年)“Rising disposable income has resulted in an increase in the spending capability towards maintaining the car using car care products. These products have several benefits towards the aesthetic appearance and the maintenance of car interior and exterior.” The global car care products market is projected to grow from USD 11.8 billion in 2019 to USD 16.1 billion in 2027 at a CAGR of 4.0 % during the …
- 疼痛管理装置の世界市場:神経刺激装置、SCS(脊髄刺激療法)、TENS、ラジオ波焼灼療法、注入ポンプPain management devices are used to manage chronic and acute pain in patients suffering from various conditions, such as cancer, neurological disorders, and musculoskeletal disorders. These devices restore the ability of patients to do everyday activities, decrease the need for oral pain medications, and improve the quality of life of patients suffering from these conditions. The global pain manag …
- 金属加工用流体の世界市場分析:製品別(ミネラル、合成、バイオベース)、用途別(ニート切削油、水溶性切削油、腐食防止油)、セグメント予測The global metalworking fluids market is expected to reach USD 11.99 billion by 2022, according to a new report by Grand View Research, Inc. Growing demand for metalworking fluids in automotives and heavy machinery owing to its properties of increasing efficiency is expected to drive market growth. Competitive pricing owing to large number of small suppliers in the market is expected to be a key f …
- 世界の熱可塑性プラスチック管市場2015The Global Thermoplastic Pipe Industry Report 2015 is a professional and in-depth study on the current state of the Thermoplastic Pipe industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Thermoplastic Pipe market analysis is provided for the international markets including development trends, competiti …
- 二酸化チタンの世界市場予測(~2021):塗料、製紙、プラスチック、化粧品、インク用途The global titanium dioxide market is projected to grow from USD 10.64 Billion in 2016 to USD 14.12 Billion by 2021, at a CAGR of 5.8% between 2016 and 2021. The increase in per capita consumption of pigments in emerging economies and increasing demand for titanium dioxide from construction and automobile industries are expected to fuel the growth of the global titanium dioxide market during the f …
- 脳出血(Brain Hemorrhage):世界の治験レビュー(2015年上半期版)Brain Hemorrhage Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Brain Hemorrhage Global Clinical Trials Review, H1, 2015" provides data on the Brain Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Brain Hemorrhage. It includes an overview of the trial numbers and their recruitment statu …
- ブラジル/ロシア/インド/中国の喉頭鏡(医療機器)市場動向(~2020)BRIC Laryngoscopes Market Outlook to 2020 Summary GlobalData’s new report, "BRIC Laryngoscopes Market Outlook to 2020", provides key market data on the BRIC Laryngoscopes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Video Laryngoscopes (Flexible Video Laryngoscopes and Portable Video Laryngoscopes) and N …
- 整形外科骨セメントの世界市場分析:エンドユーザー別(病院、外来手術センター、専門診療所)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA)、セグメント予測、2014-2025The global orthopedic bone cement market is expected to reach USD 1.1 billion by 2025, according to a new report by Grand View Research, Inc. Growing number of orthopedic surgeries is one of the key factors expected to drive revenue growth in coming few years.Orthopedic bone cement helps support and anchor artificial joints and fractured bones. It works by filling the empty space between the bone …
- テレマティクス:技術、事業機会、特許分析Coupled with the ever-evolving ICT and electronic control system technologies, telematics that enable the integration of computing, communications, control, and transport technologies has witnessed a bloom over the years. This report provides an overview of telematics development and its market outlook; examines strategic and patent deployment of established players in the industry such as Bosch, …
- Bronchopulmonary Dysplasia:グローバル臨床試験レビューH1, 2013Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013" provides data on the Bronchopulmonary Dysplasia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bronchopulmonary Dysplasia. It includes an overview of the t …